Tirzepatide has quickly become one of the most talked-about medications for weight loss. Originally developed to help manage type 2 diabetes, it is now also approved to treat obesity and overweight in eligible adults under the brand name Zepbound. Clinical trials have shown that many people lost 20% or more of their body weight while taking tirzepatide alongside healthy lifestyle changes, making it one of the most effective prescription weight loss medications available today.
If you’re just starting to learn about tirzepatide, this guide explains how it works, what clinical studies have found, how it compares with other weight loss medications, and what to know before considering treatment.
What Is Tirzepatide?
Tirzepatide is a once-weekly injectable medication developed by Eli Lilly. It belongs to a newer class of medications known as dual GIP and GLP-1 receptor agonists, meaning it activates two hormone receptors involved in appetite regulation and blood sugar control. Unlike earlier GLP-1 medications that target a single receptor, tirzepatide works on both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action is believed to contribute to its significant effects on weight loss and blood sugar management.Â
Tirzepatide is available in the United States under two FDA-approved brand names:
| Brand Name | Approved Use |
| Mounjaro | To improve blood sugar control in adults with type 2 diabetes |
| Zepbound | For chronic weight management in adults with obesity or overweight and at least one weight-related medical condition |
Although both medications contain the same active ingredient, they are approved for different indications and should only be used under the guidance of a licensed healthcare provider.Â
How Does Tirzepatide Work?
One reason tirzepatide has attracted so much attention is that it works differently from older weight loss medications. Instead of targeting a single hormone pathway, it activates both the GIP and GLP-1 receptors, two hormones involved in appetite, blood sugar regulation, and digestion. Researchers believe this dual action plays an important role in the amount of weight loss seen in clinical trials.Â
In practical terms, tirzepatide helps by:
- Eating less because hunger is reduced
- Feeling full for longer after meals
- Slowing how quickly food leaves the stomach
- Improving the body’s response to insulin and helping regulate blood sugarÂ
These effects make it easier for many people to maintain a calorie deficit over time, which is a key factor in achieving weight loss.
How Much Weight Can You Lose?
One of the biggest reasons tirzepatide has gained so much attention is the amount of weight loss reported in clinical trials.
The largest study, SURMOUNT-1, followed 2,539 adults with obesity or overweight who did not have type 2 diabetes. Participants received a once-weekly injection of tirzepatide or a placebo for 72 weeks while also following lifestyle recommendations.Â
Average weight loss increased as the dose increased:
| Weekly Dose | Average Weight Loss |
| 5 mg | 15.0% |
| 10 mg | 19.5% |
| 15 mg | 20.9% |
| Placebo | 3.1% |
The highest dose produced an average weight loss of 20.9%, and more than half of participants lost at least 20% of their body weight. Nearly 1 in 3 people taking the 15 mg dose lost 25% or more, results that were rarely seen with weight loss medications before tirzepatide.Â
More recent research has shown that many participants maintained substantial weight loss with continued treatment, supporting tirzepatide as a long-term option for chronic weight management.Â
How Does Tirzepatide Compare to Wegovy?
Tirzepatide and semaglutide (Wegovy) are both FDA-approved medications for chronic weight management, but they work differently. Tirzepatide activates both the GIP and GLP-1 receptors, while semaglutide targets only the GLP-1 receptor. Researchers believe this difference may contribute to the greater weight loss seen with tirzepatide in clinical trials.Â
Here’s how the average weight loss compares:
| Medication | Hormone Target | Average Weight Loss* |
| Wegovy (semaglutide) | GLP-1 | 13.7% |
| Zepbound (tirzepatide) | GIP + GLP-1 | 20.2% |
*Results are from the SURMOUNT-5 head-to-head trial after 72 weeks of treatment.
While both medications helped participants achieve significant weight loss, tirzepatide produced greater average weight loss and a higher percentage of participants reached weight loss milestones of 10%, 15%, 20%, and 25%.
Common Side Effects
Like other medications that target the GLP-1 pathway, tirzepatide most commonly causes gastrointestinal side effects. These symptoms are usually reported during the first few weeks of treatment or while the dose is being increased. Most cases are mild to moderate and improve over time.Â
The most commonly reported side effects include:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Stomach pain
- Indigestion
Although most people tolerate tirzepatide well, some participants in clinical trials stopped treatment because of gastrointestinal side effects, particularly at higher doses. Your healthcare provider may recommend gradually increasing the dose to help reduce these symptoms.Â
Who Can Take Tirzepatide?
Tirzepatide is approved for adults with obesity and for adults who are overweight and have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It is also approved to improve blood sugar control in adults with type 2 diabetes under a different brand name.Â
Whether tirzepatide is the right treatment depends on several factors, including your medical history, current health conditions, and overall treatment goals. A healthcare provider can help determine whether it is an appropriate option and discuss the potential benefits and risks.
What’s New in Tirzepatide Research?
Although tirzepatide is already approved for chronic weight management, researchers continue to study its potential benefits in other areas. Recent clinical trials have evaluated the medication in people with obstructive sleep apnea, heart failure with preserved ejection fraction (HFpEF), and obesity-related conditions, with encouraging results. These studies may expand our understanding of where tirzepatide fits in obesity and metabolic care.Â
Researchers are also collecting long-term data to better understand how well weight loss is maintained over time and the medication’s effects on overall health beyond weight reduction.
How Long Does It Take to See Results?
Weight loss with tirzepatide doesn’t happen overnight. Most people begin to notice changes within the first few weeks, but the greatest results are typically seen after several months of consistent treatment.
In the SURMOUNT-1 clinical trial, participants continued losing weight throughout the 72-week study, with weight loss gradually increasing as treatment continued. This is one reason healthcare providers encourage patients to stay consistent with both the medication and healthy lifestyle habits.
Everyone responds differently, and factors such as the prescribed dose, diet, physical activity, and overall health can all influence individual results.
Final Thoughts
Tirzepatide has become one of the most effective prescription medications available for chronic weight management, with clinical trials showing average weight loss of up to 20.9% over 72 weeks. Its dual action on the GIP and GLP-1 receptors sets it apart from earlier medications and has helped reshape the way obesity is treated.Â
While no treatment works the same for everyone, the growing body of research continues to support tirzepatide as an important option for eligible adults living with obesity or overweight. As scientists learn more through ongoing studies, its role in weight management and metabolic health will likely continue to evolve.
Sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. 2022;387:205-216.
- Jastreboff AM, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). The New England Journal of Medicine. 2025.
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Tirzepatide vs Placebo on Weight Maintenance in Adults With Obesity or Overweight (SURMOUNT-4). JAMA. 2023;330(13):1234-1245.
- U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. November 8, 2023.
- Frias JP, Nauck MA, Van J, et al. Efficacy and Safety of a Dual GIP and GLP-1 Receptor Agonist in Patients With Type 2 Diabetes. The Lancet. 2018;392(10160):2180-2193.
